Antibiotic Management in Bronchiectasis

Charles S Haworth; Roderigo Andres Floto

doi:10.1016/j.ccm.2021.11.009

Antibiotic Management in Bronchiectasis

Clin Chest Med. 2022 Mar;43(1):165-177. doi: 10.1016/j.ccm.2021.11.009.

Authors

Charles S Haworth¹, Roderigo Andres Floto²

Affiliations

¹ Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge CB2 0AY, UK; Department of Medicine, University of Cambridge, Cambridge, UK. Electronic address: charles.haworth@nhs.net.
² Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge CB2 0AY, UK; University of Cambridge Molecular Immunity Unit, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.

PMID: 35236556
DOI: 10.1016/j.ccm.2021.11.009

Abstract

Antibiotics are an essential component of the management of patients with bronchiectasis. This article reviews the role of antibiotics in the treatment of exacerbations, for maintenance therapy to reduce exacerbation frequency, and for eradicating potentially harmful organisms such as Pseudomonas aeruginosa.

Keywords: Antibiotics; Bronchiectasis; Chronic suppressive; Eradication; Exacerbation; Intravenous; Nebulized; Oral.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Anti-Bacterial Agents / therapeutic use
Bronchiectasis* / drug therapy
Humans

Substances

Anti-Bacterial Agents